Mutant KRAS-IL-1β addiction is mediated via secretion of the glycoprotein versican (VCAN) by tumor cells, which inhibits the NF-κΒ kinase (IKK) β in macrophages, resulting in IL-1β release into the tumor microenvironment. The gene discussed is KRAS; the disease is neoplasm.